Agreements (Details 3) (Sanofi, USD $)	1 Months Ended	120 Months Ended				12 Months Ended		12 Months Ended		1 Months Ended			1 Months Ended			21 Months Ended
	Jul. 31, 2003 Discover, Develop and Commercialize item	Jun. 30, 2013 Discover, Develop and Commercialize	Jul. 31, 2003 Discover, Develop and Commercialize Maximum	Jul. 31, 2003 Discover, Develop and Commercialize Development milestones	Jul. 31, 2003 Discover, Develop and Commercialize Regulatory milestones	Jun. 30, 2013 Discover, Develop and Commercialize Undisclosed Target	Jun. 30, 2013 Discover, Develop and Commercialize Undisclosed Target Phase I clinical trial	Jun. 30, 2013 Discover, Develop and Commercialize SAR3419 Phase IIb clinical trial	Jun. 30, 2013 Discover, Develop and Commercialize SAR3419 Development milestones Phase III clinical trial	Sep. 30, 2010 Discover, Develop and Commercialize SAR566658 Phase I clinical trial	Jun. 30, 2013 Discover, Develop and Commercialize SAR566658 Development milestones Phase IIb clinical trial	Jun. 30, 2013 Discover, Develop and Commercialize SAR650984 Development milestones Phase IIb clinical trial	Aug. 31, 2011 Right-to-test agreement	Aug. 31, 2008 Right-to-test agreement	Dec. 31, 2006 Right-to-test agreement	Aug. 31, 2008 Right-to-test agreement	Dec. 31, 2006 Right-to-test agreement Maximum	Dec. 31, 2006 Right-to-test agreement Development milestones	Dec. 31, 2006 Right-to-test agreement Regulatory milestones
Collaborative Agreements disclosures
Number of undisclosed compounds with exclusive licenses	2
Potential milestone payments receivable			$ 21,500,000	$ 7,500,000	$ 14,000,000		$ 1,000,000		$ 3,000,000		$ 3,000,000	$ 3,000,000					$ 30,000,000	$ 10,000,000	$ 20,000,000
Payments received under collaboration agreement		16,500,000				500,000		3,000,000		1,000,000				3,500,000	500,000	4,000,000
License exercise fee, per license															2,000,000
Term of agreement															3 years
Term of extension of agreement													3 years
Payments for extension of agreement													$ 2,000,000